

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 5, 2021

HARVARD BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-33957
(Commission File Number)

04-3306140
(I.R.S. Employer Identification Number)

84 October Hill Road, Holliston, MA 01746
(Address of Principal Executive Offices) (Zip Code)

(508) 893-8999
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	HBIO	The NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2021, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and six months ended June 30, 2021 and the details of a related conference call to be held at 8:00 AM ET on August 5, 2021. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release issued by Harvard Bioscience, Inc. on August 5, 2021
104	Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HARVARD BIOSCIENCE, INC.

Date: August 5, 2021

By: /s/ James Green
James Green
Chief Executive Officer

Harvard Bioscience Announces Second Quarter 2021 Financial Results

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions

- Revenue up 25% year-over-year as sales momentum continues
- Cellular and Molecular (CMT) product revenue up 22%
- Pre-clinical product revenue up 20%
- Operating margins impacted by higher global supply chain costs

HOLLISTON, Mass., August 5, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the three and six months ended June 30, 2021.

Jim Green, Chairman and CEO said, "Demand for our pre-clinical products remains very strong, with revenue up 20% over prior year, and also up significantly over pre-Covid levels. Our CMT products also experienced meaningful growth, up 22% over prior year as academic lab sales continue to recover. Operating income on a GAAP and adjusted basis was negatively impacted by increased material, freight and labor efficiency costs associated with ongoing global supply disruptions. However, adjusted operating margins continue to exceed pre-COVID margin levels."

Green concluded, "Expanding demand from CRO/pharma combined with continuing academic lab recovery and a strong backlog supports our improving revenue outlook in spite of global supply disruptions; we now expect revenue growth of 12% to 15% for fiscal 2021 compared to 2020. Although supply disruptions are forcing extra costs in the short term, we still expect adjusted operating margin expansion to the mid-teens for the year."

Quarterly Financial Results Summary

	<u>Q2'21</u>		<u>Q2'20</u>	
Revenue	\$	29.2 million	\$	23.3 million
Operating Income (GAAP)	\$	0.1 million	\$	0.6 million
Adjusted Operating Income	\$	4.3 million	\$	4.1 million
Operating Margin (GAAP)		0.2 %		2.4 %
Adjusted Operating Margin		14.6 %		17.7 %
Loss Per Share (GAAP)	\$	(0.01)	\$	(0.04)
Adjusted Diluted Earnings Per Share	\$	0.06	\$	0.05
Net Debt*	\$	38.2 million	\$	42.1 million

* Debt outstanding less cash and cash equivalents

Please refer to the exhibits below for a reconciliation of certain non-GAAP to GAAP financial measures, including operating income, net income and loss, diluted earnings per share and adjusted EBITDA. Please see “Use of Non-GAAP Financial Information” for additional information regarding our use of such adjusted financial information.

Webcast and Conference Call Details

Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID# 6293853.

The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. A slide presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins. To listen to the webcast, log on to the webcast at: <http://investor.harvardbioscience.com/> and click on the Earnings Call icon.

Use of Non-GAAP Financial Information

In this press release, we have included non-GAAP financial information including adjusted operating income, adjusted net income, adjusted diluted earnings per share, and adjusted EBITDA. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration initiatives, impairment charges, severance, restructuring and other business transformation expenses, and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our adjusted operating income, adjusted net income (loss), adjusted earnings (loss) per diluted share, and adjusted EBITDA are included as exhibits below in this press release.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

About Harvard Bioscience

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, industry outlook, the impact of the COVID-19 pandemic on the Company's business, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020, and in our other filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein may cause the Company's actual results to differ materially from those in the forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

For investor inquiries, please contact Michael A. Rossi, Chief Financial Officer at (508) 893-8999.

HARVARD BIOSCIENCE, INC.
Consolidated Statements of Operations
(unaudited, in thousands, except per share data)

	Three Months Ended		Six Months Ended	
	June 30, 2021	June 30, 2020	June 30, 2021	June 30, 2020
Revenues	\$ 29,197	\$ 23,308	\$ 56,186	\$ 47,079
Cost of revenues	12,844	9,452	24,402	20,241
Gross profit	16,353	13,856	31,784	26,838
Operating expenses:				
Sales and marketing expenses	5,730	4,279	11,116	9,858
General and administrative expenses	6,399	5,670	12,732	12,429
Research and development expenses	2,701	1,897	5,188	4,387
Amortization of intangible assets	1,465	1,454	2,929	2,881
Total operating expenses	16,295	13,300	31,965	29,555
Operating income	58	556	(181)	(2,717)
Other expense:				
Interest expense	(377)	(1,233)	(788)	(2,532)
Other expense, net	(313)	(191)	(347)	(80)
Total other expense	(690)	(1,424)	(1,135)	(2,612)
Loss before income taxes	(632)	(868)	(1,316)	(5,329)
Income tax expense	(222)	713	(237)	768
Net loss	\$ (410)	\$ (1,581)	\$ (1,079)	\$ (6,097)
Loss per common share:				
Basic and diluted	\$ (0.01)	\$ (0.04)	\$ (0.03)	\$ (0.16)
Weighted-average common shares:				
Basic and diluted	40,152	38,468	39,960	38,389

HARVARD BIOSCIENCE, INC.
Condensed Consolidated Balance Sheets
(unaudited, in thousands)

	<u>June 30, 2021</u>	<u>December 31, 2020</u>
Assets		
Cash and cash equivalents	\$ 6,237	\$ 8,317
Accounts receivables	17,391	17,766
Inventories	24,709	22,262
Other current assets	5,220	3,355
Total current assets	53,557	51,700
Property, plant and equipment	3,429	3,960
Goodwill and other intangibles	88,934	91,741
Other long-term assets	8,051	8,853
Total assets	<u>\$ 153,971</u>	<u>\$ 156,254</u>
Liabilities and Stockholders' Equity		
Current portion, long-term debt	\$ 2,220	\$ 1,721
Other current liabilities	21,048	19,332
Total current liabilities	23,268	21,053
Long-term debt	40,921	46,286
Other long-term liabilities	11,081	12,234
Stockholders' equity	78,701	76,681
Total liabilities and stockholders' equity	<u>\$ 153,971</u>	<u>\$ 156,254</u>

HARVARD BIOSCIENCE, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)

	Six Months Ended	
	June 30, 2021	June 30, 2020
Cash flows from operating activities:		
Net loss	\$ (1,079)	\$ (6,097)
Adjustments to operating cash flows	5,789	6,045
Changes in operating assets and liabilities	(2,905)	5,296
Net cash provided by operating activities	1,805	5,244
Cash flows from investing activities:		
Additions to property, plant and equipment	(357)	(524)
Addition to intangible assets	(150)	—
Net cash used in investing activities	(507)	(524)
Cash flows from financing activities:		
Proceeds from borrowings	—	6,115
Repayments of debt	(5,000)	(16,411)
Payments of debt issuance costs	(102)	—
Proceeds from exercise of stock options	2,759	187
Taxes related to net share settlement of equity awards	(990)	(262)
Net cash used in financing activities	(3,333)	(10,371)
Effect of exchange rate changes on cash	(45)	(55)
Decrease in cash and cash equivalents	(2,080)	(5,706)
Cash and cash equivalents at the beginning of period	8,317	8,335
Cash and cash equivalents at the end of period	\$ 6,237	\$ 2,629

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Three Months Ended June 30, 2021
(in thousands, except per share data)

Statement of Operations	GAAP	Stock-Based Compensation	Acquired Assets Amortization & Impairments	Severance, Restructuring, Transformation	Income Taxes	ADJUSTED
Revenues	\$ 29,197	—	—	—	—	\$ 29,197
Cost of revenues	12,844	(31)	(17)	(100)	—	12,696
Gross profit	16,353	31	17	100	—	16,501
Gross Margin	56.0%					56.5%
Operating expenses:						
Sales and marketing expenses	5,730	(131)	(2)	(73)	—	5,524
General and administrative expenses	6,399	(969)	(16)	(1,108)	—	4,306
Research and development expenses	2,701	(33)	(11)	(249)	—	2,408
Amortization of intangible assets	1,465	—	(1,465)	—	—	—
Total operating expenses	16,295	(1,133)	(1,494)	(1,430)	—	12,238
Operating Expenses - % of Revenue	55.8%					41.9%
Operating income	58	1,164	1,511	1,530	—	4,263
Operating Margin	0.2%					14.6%
Other expense:						
Interest expense	(377)	—	—	—	—	(377)
Other expense, net	(313)	—	—	—	—	(313)
Total other expense	(690)	—	—	—	—	(690)
(Loss) income before income taxes	(632)	1,164	1,511	1,530	—	3,573
Income tax (benefit) expense	(222)	—	—	—	1,040	818
Net (loss) income	\$ (410)	\$ 1,164	\$ 1,511	\$ 1,530	\$ (1,040)	\$ 2,755
(Loss) income per share	\$ (0.01)					\$ 0.06
Diluted weighted average common shares	40,152					43,425

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Three Months Ended June 30, 2020
(in thousands, except per share data)

Statement of Operations	GAAP	Stock-Based Compensation	Acquired Assets Amortization & Impairments	Severance, Restructuring, Transformation	Income Taxes	ADJUSTED
Revenues	\$ 23,308	—	—	—	—	\$ 23,308
Cost of revenues	9,452	(14)	(20)	(43)	—	9,375
Gross profit	13,856	14	20	43	—	13,933
Gross Margin	59.4%					59.8%
Operating expenses:						
Sales and marketing expenses	4,279	(62)	(2)	16	—	4,231
General and administrative expenses	5,670	(645)	(18)	(1,260)	—	3,747
Research and development expenses	1,897	(48)	(14)	—	—	1,835
Amortization of intangible assets	1,454	—	(1,454)	—	—	—
Total operating expenses	13,300	(755)	(1,488)	(1,244)	—	9,813
Operating Expenses - % of Revenue	57.1%					42.1%
Operating income	556	769	1,508	1,287	—	4,120
Operating Margin	2.4%					17.7%
Other expense:						
Interest expense	(1,233)	—	—	—	—	(1,233)
Other expense, net	(191)	—	—	—	—	(191)
Total other expense	(1,424)	—	—	—	—	(1,424)
(Loss) income before income taxes	(868)	769	1,508	1,287	—	2,696
Income tax (benefit) expense	713	—	—	—	(103)	610
Net (loss) income	\$ (1,581)	\$ 769	\$ 1,508	\$ 1,287	\$ 103	\$ 2,086
(Loss) income per share	\$ (0.04)					\$ 0.05
Diluted weighted average common shares	38,468					39,593

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Six Months Ended June 30, 2021
(in thousands, except per share data)

Statement of Operations	GAAP	Stock-Based Compensation	Acquired Assets Amortization & Impairments	Severance, Restructuring, Transformation	Income Taxes	ADJUSTED
Revenues	\$ 56,186	—	—	—	—	\$ 56,186
Cost of revenues	24,402	(51)	(36)	(153)	—	24,162
Gross profit	31,784	51	36	153	—	32,024
Gross Margin	56.6%					57.0%
Operating expenses:						
Sales and marketing expenses	11,116	(224)	(4)	(114)	—	10,774
General and administrative expenses	12,732	(1,803)	(33)	(1,954)	—	8,942
Research and development expenses	5,188	(54)	(22)	(294)	—	4,818
Amortization of intangible assets	2,929	—	(2,929)	—	—	—
Total operating expenses	31,965	(2,081)	(2,988)	(2,362)	—	24,534
Operating Expenses - % of Revenue	56.9%					43.7%
Operating (loss) income	(181)	2,132	3,024	2,515	—	7,490
Operating Margin	-0.3%					13.3%
Other expense:						
Interest expense	(788)	—	—	—	—	(788)
Other expense, net	(347)	—	—	—	—	(347)
Total other expense	(1,135)	—	—	—	—	(1,135)
(Loss) income before income taxes	(1,316)	2,132	3,024	2,515	—	6,355
Income tax (benefit) expense	(237)	—	—	—	1,784	1,547
Net (loss) income	<u>\$ (1,079)</u>	<u>\$ 2,132</u>	<u>\$ 3,024</u>	<u>\$ 2,515</u>	<u>\$ (1,784)</u>	<u>\$ 4,808</u>
(Loss) income per share	<u>\$ (0.03)</u>					<u>\$ 0.11</u>
Diluted weighted average common shares	<u>39,960</u>					<u>42,954</u>

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Six Months Ended June 30, 2020
(in thousands, except per share data)

Statement of Operations	GAAP	Stock-Based Compensation	Acquired Assets Amortization & Impairments	Severance, Restructuring, Transformation	Income Taxes	ADJUSTED
Revenues	\$ 47,079	—	—	—	—	\$ 47,079
Cost of revenues	20,241	(24)	(40)	(2)	—	20,175
Gross profit	26,838	24	40	2	—	26,904
Gross Margin	57.0%					57.1%
Operating expenses:						
Sales and marketing expenses	9,858	(113)	(4)	(110)	—	9,631
General and administrative expenses	12,429	(1,341)	(35)	(2,646)	—	8,407
Research and development expenses	4,387	(84)	(31)	—	—	4,272
Amortization of intangible assets	2,881	—	(2,881)	—	—	-
Total operating expenses	29,555	(1,538)	(2,951)	(2,756)	—	22,310
Operating Expenses - % of Revenue	62.8%					47.4%
Operating (loss) income	(2,717)	1,562	2,991	2,758	—	4,594
Operating Margin	-5.8%					9.8%
Other expense:						
Interest expense	(2,532)	—	—	—	—	(2,532)
Other expense, net	(80)	—	—	—	—	(80)
Total other expense	(2,612)	—	—	—	—	(2,612)
(Loss) income before income taxes	(5,329)	1,562	2,991	2,758	—	1,982
Income tax (benefit) expense	768	—	—	—	(391)	377
Net (loss) income	\$ (6,097)	\$ 1,562	\$ 2,991	\$ 2,758	\$ 391	\$ 1,605
(Loss) income per share	\$ (0.16)					\$ 0.04
Diluted weighted average common shares	38,389					39,461

HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
(in thousands)

	Three Months Ended		Six Months Ended	
	June 30, 2021	June 30, 2020	June 30, 2021	June 30, 2020
Net loss	\$ (410)	\$ (1,581)	\$ (1,079)	\$ (6,097)
Amortization of intangible assets	1,465	1,454	2,929	2,881
Depreciation expense	446	498	891	982
Interest expense	377	1,233	788	2,532
Income taxes	(222)	713	(237)	768
Stock-based compensation expense	1,164	769	2,132	1,562
Severance, restructuring and transformation costs	1,530	1,287	2,515	2,758
Adjusted EBITDA	\$ 4,350	\$ 4,373	\$ 7,939	\$ 5,386